Celltrion’s Biosimilar to Remicade Likely to be Approved for All Indications
February 12, 2016
Randi Hernandez
PharmTech.com / BioPharm International
Axinn counsel Stacie Ropka was quoted in the PharmTech.com and BioPharm International article, "Celltrion’s Biosimilar to Remicade Likely to be Approved for All Indications."